Research programme: anti-infective antibody therapeutics - AbCellera/RQ Bio
Latest Information Update: 27 Mar 2023
Price :
$50 *
At a glance
- Originator Abcellera; RQ Bio
- Class Anti-infectives; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Infections